According to the Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, endocrine therapy combined with anti‐HER2 therapy may be considered for patients with ER‐positive HER2‐positive metastatic breast cancer and for whom chemotherapy is contraindicated.7 The gene discussed is ESR1; the disease is breast carcinoma.